Cargando…
Identification of a Small Molecule Inhibitor of RAD52 by Structure-Based Selection
It has been reported that inhibition of RAD52 either by specific shRNA or a small peptide aptamer induced synthetic lethality in tumor cell lines carrying BRCA1 and BRCA2 inactivating mutations. Molecular docking was used to screen two chemical libraries: 1) 1,217 FDA approved drugs, and 2) 139,735...
Autores principales: | Sullivan, Katherine, Cramer-Morales, Kimberly, McElroy, Daniel L., Ostrov, David A., Haas, Kimberly, Childers, Wayne, Hromas, Robert, Skorski, Tomasz |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4718542/ https://www.ncbi.nlm.nih.gov/pubmed/26784987 http://dx.doi.org/10.1371/journal.pone.0147230 |
Ejemplares similares
-
Targeting BRCA1- and BRCA2-deficient cells with RAD52 small molecule inhibitors
por: Huang, Fei, et al.
Publicado: (2016) -
RAD52 as a Potential Target for Synthetic Lethality-Based Anticancer Therapies
por: Toma, Monika, et al.
Publicado: (2019) -
Interaction of yeast Rad51 and Rad52 relieves Rad52-mediated inhibition of de novo telomere addition
por: Epum, Esther A., et al.
Publicado: (2020) -
Simultaneous Targeting of PARP1 and RAD52 Triggers Dual Synthetic Lethality in BRCA-Deficient Tumor Cells
por: Sullivan-Reed, Katherine, et al.
Publicado: (2018) -
Small-molecule inhibitors identify the RAD52-ssDNA interaction as critical for recovery from replication stress and for survival of BRCA2 deficient cells
por: Hengel, Sarah R, et al.
Publicado: (2016)